Ofir Noah Nevo1, Catherine R Lesko2, Bradford Colwell2, Craig Ballard2, Stephen R Cole2, W Christopher Mathews2. 1. Ofir Noah Nevo, Pharm.D., is Pharmacy Resident, University of California San Diego (UCSD). Catherine R. Lesko, Ph.D., M.P.H., is Research Associate, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Bradford Colwell, Pharm.D., AAHIVP, is HIV Pharmacist Specialist; and Craig Ballard,, Pharm.D., AAHIVP, is HIV Pharmacist Specialist, UCSD. Stephen R. Cole, Ph.D., is Professor and Director of Graduate Studies, Department of Epidemiology, University of North Carolina, Chapel Hill. W. Christopher Mathews, M.D., M.S.P.H., is Professor of Clinical Medicine, UCSD. ofir.nevo@ucdenver.edu. 2. Ofir Noah Nevo, Pharm.D., is Pharmacy Resident, University of California San Diego (UCSD). Catherine R. Lesko, Ph.D., M.P.H., is Research Associate, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Bradford Colwell, Pharm.D., AAHIVP, is HIV Pharmacist Specialist; and Craig Ballard,, Pharm.D., AAHIVP, is HIV Pharmacist Specialist, UCSD. Stephen R. Cole, Ph.D., is Professor and Director of Graduate Studies, Department of Epidemiology, University of North Carolina, Chapel Hill. W. Christopher Mathews, M.D., M.S.P.H., is Professor of Clinical Medicine, UCSD.
Abstract
PURPOSE: The impact of pharmacist-assisted management (PAM) of pharmacotherapy for patients with human immunodeficiency virus (HIV) infection was investigated. METHODS: A retrospective cohort analysis was conducted to evaluate antiretroviral therapy (ART) outcomes in treatment-naive patients initiated on ART at an HIV clinic. Eligible patients enrolled in the clinic during the period 1999-2013 were classified into two groups: those referred to a clinic-based HIV pharmacist for initiation of ART (the PAM group) and those managed by a primary care provider (the control group). The primary study objective was the median time to viral suppression; secondary objectives included the durability of response to the first ART regimen. Relative hazards for the events of interest were estimated using a marginal structural Cox proportional hazards model and Kaplan-Meier curves, with inverse probability weights used to control for selection and confounding bias. RESULTS: Patients referred for PAM services (n = 819) typically had higher baseline viral loads and lower CD4+ cell counts than those in the control group (n = 436). The likelihood of viral suppression during the first two years after ART initiation was significantly higher in the PAM group versus the control group (hazard ratio, 1.37; 95% confidence interval, 1.18-1.59; p < 0.0001). The median durability of the first ART regimen was 100 months in the PAM group versus 44 months in the control group (p > 0.05). CONCLUSION: In treatment-naive patients, suppression of HIV viral load occurred earlier when pharmacists assisted with initiating ART than when ART was initiated without that assistance.
PURPOSE: The impact of pharmacist-assisted management (PAM) of pharmacotherapy for patients with human immunodeficiency virus (HIV) infection was investigated. METHODS: A retrospective cohort analysis was conducted to evaluate antiretroviral therapy (ART) outcomes in treatment-naive patients initiated on ART at an HIV clinic. Eligible patients enrolled in the clinic during the period 1999-2013 were classified into two groups: those referred to a clinic-based HIV pharmacist for initiation of ART (the PAM group) and those managed by a primary care provider (the control group). The primary study objective was the median time to viral suppression; secondary objectives included the durability of response to the first ART regimen. Relative hazards for the events of interest were estimated using a marginal structural Cox proportional hazards model and Kaplan-Meier curves, with inverse probability weights used to control for selection and confounding bias. RESULTS:Patients referred for PAM services (n = 819) typically had higher baseline viral loads and lower CD4+ cell counts than those in the control group (n = 436). The likelihood of viral suppression during the first two years after ART initiation was significantly higher in the PAM group versus the control group (hazard ratio, 1.37; 95% confidence interval, 1.18-1.59; p < 0.0001). The median durability of the first ART regimen was 100 months in the PAM group versus 44 months in the control group (p > 0.05). CONCLUSION: In treatment-naive patients, suppression of HIV viral load occurred earlier when pharmacists assisted with initiating ART than when ART was initiated without that assistance.
Authors: T E Yamashita; J P Phair; A Muñoz; J B Margolick; R Detels; S J O'Brien; J W Mellors; S M Wolinsky; L P Jacobson Journal: AIDS Date: 2001-04-13 Impact factor: 4.177
Authors: Chanelle J Howe; Stephen R Cole; Daniel J Westreich; Sander Greenland; Sonia Napravnik; Joseph J Eron Journal: Epidemiology Date: 2011-11 Impact factor: 4.822
Authors: Paul W Abramowitz; Rita Shane; Lisa A Daigle; Karen A Noonan; Donald E Letendre Journal: Am J Health Syst Pharm Date: 2012-11-15 Impact factor: 2.637
Authors: D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh Journal: Ann Intern Med Date: 2000-07-04 Impact factor: 25.391
Authors: David Townsend; Jesús Troya; Ivana Maida; Leticia Pérez-Saleme; Giovanni Satta; Aimee Wilkin; Pablo Barreiro; P Samuel Pegram; Vincent Soriano; Maria Stella Mura; Marina Núñez Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2009 Sep-Oct
Authors: Miguel A Hernán; Mara McAdams; Nuala McGrath; Emilie Lanoy; Dominique Costagliola Journal: Stat Methods Med Res Date: 2008-11-26 Impact factor: 3.021
Authors: Sharon Walmsley; Barry Bernstein; Martin King; José Arribas; Gildon Beall; Peter Ruane; Margaret Johnson; David Johnson; Richard Lalonde; Anthony Japour; Scott Brun; Eugene Sun Journal: N Engl J Med Date: 2002-06-27 Impact factor: 91.245
Authors: Catherine R Lesko; Lisa P Jacobson; Keri N Althoff; Alison G Abraham; Stephen J Gange; Richard D Moore; Sharada Modur; Bryan Lau Journal: Int J Epidemiol Date: 2018-04-01 Impact factor: 7.196
Authors: Thomas J Dilworth; Pamela W Klein; Renée-Claude Mercier; Matthew E Borrego; Bernadette Jakeman; Steven D Pinkerton Journal: J Manag Care Spec Pharm Date: 2018-02
Authors: C G R C Molino; Renata Cavalcanti Carnevale; Aline Teotonio Rodrigues; Patricia Moriel; Priscila Gava Mazzola Journal: Saudi Pharm J Date: 2016-11-15 Impact factor: 4.330